Antitumor Activity Reported With Lenvatinib/Pembrolizumab in Metastatic RCC After Disease Progression on ICI Therapy
Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.